Silexion Therapeutics Corp (SLXN)
SLXN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:InterestAndDividendIncomeOperating), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/0001178913-26-000953-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SLXN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Israel |
| IPO year | Not reported by the screener |
| SEC CIK | 0002022416 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | Cayman Islands |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $155K |
| Net income | -$11.9M |
| Operating income | -$11.6M |
| Net margin | -7685.2% |
| Operating margin | -7504.5% |
| Revenue growth | +453.6% |
| Cash | $6.0M |
| Total assets | $7.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 7.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Under these circumstances, in accordance with the requirements of Accounting Standards Codification ( ASC ) 205-40, management has concluded that there is substantial doubt about the Company's ability to continue as a going concern, as management believes its current funds will be sufficient to fund its operations for only several months from the date these financial statements are issued." | 10-Q 2026-11-12 |
| Cash and burn | $4.8M cash; operating cash flow -$2.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 649,528 (2026-11-12); 3,126,642 a year earlier. 1y figure adjusted for splits (1-for-240 overall). | Cover page 2026-11-12 |
| Reverse splits, 3 years | 3; latest 1-for-24 on 2026-11-11 | Source 2026-11-11 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-10-28 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-09-25 |
| Auditor | Kesselman & Kesselman C.P.A.s, Tel-Aviv, Israel | PCAOB Form AP 2026-04-12 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $31K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $18K | -$2.5M | -$2.1M | $4.8M | No debt tags | $133K | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $14K | -$3.6M | -$2.9M | $2.2M | No debt tags | $154K | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $32K | -$2.7M | -$3.6M | $2.4M | No debt tags | $184K | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $69K | -$4.4M | -$3.0M | $6.0M | No debt tags | $154K | 10-K 2026-03-17 |
| Q3 2025 2025-09-30 | $39K | -$3.3M | -$2.8M | $9.2M | No debt tags | $88K | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $44K | -$2.5M | -$2.5M | $3.5M | No debt tags | $49K | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $2K | -$1.7M | -$2.5M | $6.2M | No debt tags | $11K | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $3K | -$1.7M | -$2.9M | $1.2M | No debt tags | $28K | 10-K 2026-03-17 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-10-28 |
| Latest annual report | 10-K/A | 2026-05-19 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-10-19 |
Source: SEC EDGAR submissions feed, 284 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -43.1% |
| 1 month | -53.1% |
| 3 months | -82.1% |
| Year to date | -99.6% |
| 1 year | -99.7% |
| From 52-week high | -99.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| SLXNW | Silexion Therapeutics Corp Warrant | $0.0042 |
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SCNI | Scinai Immunotherapeutics Ltd. | $0.4041 | +1.02% | $1.1M |
| CLDI | Calidi Biotherapeutics Inc. | $0.6023 | -3.15% | $2.2M |
| VIVS | VivoSim Labs Inc. | $0.1237 | -2.68% | $2.5M |
| CELZ | Creative Medical Technology Holdings Inc. | $0.5201 | -1.51% | $4.0M |
| LIMN | Liminatus Pharma Inc. | $2.97 | -0.67% | $4.0M |
| CRIS | Curis Inc. | $0.4358 | -2.07% | $4.1M |
| BTTC | Black Titan Corporation | $0.2873 | -9.20% | $4.3M |
| AIM | AIM ImmunoTech Inc. | $0.1310 | -8.77% | $5.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier